Non-Hodgkin’s Lymphoma

P=N/A, N=135, Completed, Institut Paoli-Calmettes | Active, not recruiting --> Completed

P2, N=23, Active, not recruiting, ImmuneOncia Therapeutics Inc. | Trial completion date: Feb 2026 --> Feb 2027

P2, N=20, Not yet recruiting, Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

P1/2, N=161, Recruiting, AstraZeneca | N=110 --> 161 | Trial completion date: May 2026 --> Apr 2029 | Trial primary completion date: May 2026 --> Apr 2029

P=N/A, N=30, Not yet recruiting, Sun Yat-sen University

In vivo validation using a MyLa xenograft model demonstrated significant tumor growth inhibition following G-1 treatment without toxicity. These findings position GPER as a promising therapeutic target in CTCL, and support further development of GPER-targeted strategies for treating CTCL.

We also demonstrated that, compared with that with each drug used as single agents, the combined 5-aza and HDAC3i treatment induced the epigenetic remodeling of DLBCL cells, which resulted in a more potent reexpression of differentiation genes, including XBP1 and ATF4. Our results highlight the importance of specifically targeting multiple layers of the epigenome to maximize the efficacy of epigenetic-based therapies.

To our knowledge, there have been only two cases previously described in the literature of LPL/WM involvement in the female genital tract; both of which had prominent involvement of the ovaries. Although exceedingly rare, LPL/WM involvement of the female genital tract should be considered on the differential diagnosis if atypical lymphoid cells or dense lymphoid aggregates are observed.

The SNORA64 interactions with apoptotic inhibitor molecules and downregulation of pro-apoptotic molecules significantly sustain cellular viability. Therefore; SNORA64 can be used to increase the cell sensitivity to death during treatment.

Although agents such as lenalidomide and Bruton's tyrosine kinase(BTK) inhibitors have demonstrated efficacy in relapsed/refractory (R/R)PVRL, their role in treatment-naïve patients remains unclear. In conclusion, the combination of Orelabrutinib, rituximab, and intravitreal MTX is a feasible therapeutic strategy for PVRL. Our findings may contribute to a potential paradigm shift in the management of this rare disease.

Compared with 18F-FDG, 68Ga-pentixafor PET/CT detected more lesions with significantly higher tracer uptake. This case suggests that, for patients with CLL/SLL, 68Ga-pentixafor PET/CT demonstrates significantly superior performance in evaluating the tumor burden and delineating the disease extent compared with 18F-FDG PET/CT.

Expression of IRTA1 alone, or either IRTA1+ or MNDA+, was less frequent among MZL with plasma cell differentiation than among MZL with classical cell morphology (p=0.063 and 0.071, respectively), albeit not significantly. IRTA1 and MNDA are sensitive and specific markers for the differential diagnosis of MZL, and they may be helpful in distinguishing MZL from histologic mimics.